LQDA vs. TVTX
LQDA (Liquidia Corporation) and TVTX (Travere Therapeutics, Inc.) are both stocks. Both operate in the Biotechnology industry within the Healthcare sector. Over the past 5 years, LQDA returned 87.74%/yr vs 25.91%/yr for TVTX. At a 0.25 correlation, their price movements are largely independent.
Performance
LQDA vs. TVTX - Performance Comparison
Loading charts...
Returns By Period
In the year-to-date period, LQDA achieves a 85.27% return, which is significantly higher than TVTX's 23.21% return.
LQDA
- 1D
- 3.31%
- 1M
- 51.06%
- YTD
- 85.27%
- 6M
- 82.52%
- 1Y
- 252.26%
- 3Y*
- 96.59%
- 5Y*
- 87.74%
- 10Y*
- —
TVTX
- 1D
- 2.77%
- 1M
- 10.52%
- YTD
- 23.21%
- 6M
- 37.30%
- 1Y
- 207.31%
- 3Y*
- 41.35%
- 5Y*
- 25.91%
- 10Y*
- 10.47%
LQDA vs. TVTX - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|---|---|---|---|
LQDA Liquidia Corporation | 85.27% | 193.28% | -2.24% | 88.85% | 30.80% | 65.08% | -30.99% | -80.26% | 95.14% |
TVTX Travere Therapeutics, Inc. | 23.21% | 119.35% | 93.77% | -57.25% | -32.25% | 13.89% | 91.94% | -37.25% | -20.82% |
Correlation
The correlation between LQDA and TVTX is 0.24, which is low. Their price movements are largely independent, making them effective diversification partners.
| Correlation | |
|---|---|
Correlation (1Y) Calculated over the trailing 1-year period | 0.24 |
Correlation (3Y) Calculated over the trailing 3-year period | 0.28 |
Correlation (5Y) Calculated over the trailing 5-year period | 0.30 |
Correlation (All Time) Calculated using the full available price history since Jul 27, 2018 | 0.25 |
Fundamentals
LQDA:
$6.46B
TVTX:
$4.33B
LQDA:
$0.24
TVTX:
-$0.49
LQDA:
20.69
TVTX:
8.20
LQDA:
59.51
TVTX:
43.81
LQDA:
$288.07M
TVTX:
$536.20M
LQDA:
$275.77M
TVTX:
$385.20M
LQDA:
$51.53M
TVTX:
$11.15M
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
LQDA vs. TVTX — Risk / Return Rank
LQDA
TVTX
LQDA vs. TVTX - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for Liquidia Corporation (LQDA) and Travere Therapeutics, Inc. (TVTX). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
| LQDA | TVTX | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | +0.82 | ||
| Sortino ratioReturn per unit of downside risk | -0.11 | ||
| Omega ratioGain probability vs. loss probability | 1.46 | 1.48 | -0.02 |
| Calmar ratioReturn relative to maximum drawdown | 7.12 | 6.23 | +0.89 |
| Martin ratioReturn relative to average drawdown | 15.88 | 14.39 | +1.49 |
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month. | |||
Loading charts...
Sharpe Ratios by Period
| LQDA | TVTX | Difference | |
|---|---|---|---|
Sharpe Ratio (1Y)Calculated over the trailing 1-year period | 3.74 | 2.92 | +0.82 |
Sharpe Ratio (5Y)Calculated over the trailing 5-year period | 1.20 | 0.39 | +0.81 |
Sharpe Ratio (10Y)Calculated over the trailing 10-year period | — | 0.18 | — |
Sharpe Ratio (All Time)Calculated using the full available price history | 0.29 | 0.30 | 0.00 |
Drawdowns
LQDA vs. TVTX - Drawdown Comparison
The maximum LQDA drawdown since its inception was -93.87%, which is greater than TVTX's maximum drawdown of -85.43%. Use the drawdown chart below to compare losses from any high point for LQDA and TVTX.
Loading charts...
Drawdown Indicators
| LQDA | TVTX | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -93.87% | -85.43% | -8.44% |
Max Drawdown (1Y)Largest decline over 1 year | -35.66% | -33.49% | -2.17% |
Max Drawdown (3Y)Largest decline over 3 years | -46.80% | -69.77% | +22.97% |
Max Drawdown (5Y)Largest decline over 5 years | -55.36% | -83.12% | +27.76% |
Max Drawdown (10Y)Largest decline over 10 years | — | -83.64% | — |
Current DrawdownCurrent decline from peak | 0.00% | -1.42% | +1.42% |
Average DrawdownAverage peak-to-trough decline | -69.65% | -41.13% | -28.52% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 16.05% | 14.49% | +1.56% |
Volatility
LQDA vs. TVTX - Volatility Comparison
Liquidia Corporation (LQDA) has a higher volatility of 28.47% compared to Travere Therapeutics, Inc. (TVTX) at 14.17%. This indicates that LQDA's price experiences larger fluctuations and is considered to be riskier than TVTX based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading charts...
Volatility by Period
| LQDA | TVTX | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 28.47% | 14.17% | +14.30% |
Volatility (6M)Calculated over the trailing 6-month period | 47.97% | 51.90% | -3.93% |
Volatility (1Y)Calculated over the trailing 1-year period | 68.06% | 71.68% | -3.62% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 73.62% | 66.44% | +7.18% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 85.75% | 58.34% | +27.41% |
Dividends
LQDA vs. TVTX - Dividend Comparison
Neither LQDA nor TVTX has paid dividends to shareholders.
Financials
LQDA vs. TVTX - Financials Comparison
This section allows you to compare key financial metrics between Liquidia Corporation and Travere Therapeutics, Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities
LQDA vs. TVTX - Profitability Comparison
LQDA - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Liquidia Corporation reported a gross profit of 132.09M and revenue of 132.87M. Therefore, the gross margin over that period was 99.4%.
TVTX - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Travere Therapeutics, Inc. reported a gross profit of 0.00 and revenue of 127.20M. Therefore, the gross margin over that period was 0.0%.
LQDA - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Liquidia Corporation reported an operating income of 61.50M and revenue of 132.87M, resulting in an operating margin of 46.3%.
TVTX - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Travere Therapeutics, Inc. reported an operating income of -36.60M and revenue of 127.20M, resulting in an operating margin of -28.8%.
LQDA - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Liquidia Corporation reported a net income of 52.86M and revenue of 132.87M, resulting in a net margin of 39.8%.
TVTX - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Travere Therapeutics, Inc. reported a net income of -37.10M and revenue of 127.20M, resulting in a net margin of -29.2%.
Frequently Asked Questions
LQDA and TVTX have a correlation of 0.24, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.
LQDA has higher volatility (28.47%) compared to TVTX (14.17%). In terms of maximum drawdown, LQDA dropped -93.87% vs TVTX's -85.43%.
LQDA currently has the higher Sharpe Ratio (3.74 vs 2.92), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.
Find the right allocation for LQDA and TVTX
Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Optimizer